Kanada - engelska - Health Canada

janssen inc - paliperidone (paliperidone palmitate) - suspension (extended-release) - 263mg - paliperidone (paliperidone palmitate) 263mg - atypical antipsychotics

Kanada - engelska - Health Canada

janssen inc - paliperidone (paliperidone palmitate) - suspension (extended-release) - 350mg - paliperidone (paliperidone palmitate) 350mg - atypical antipsychotics

Kanada - engelska - Health Canada

janssen inc - paliperidone (paliperidone palmitate) - suspension (extended-release) - 525mg - paliperidone (paliperidone palmitate) 525mg - atypical antipsychotics

Kanada - engelska - Health Canada

janssen inc - paliperidone (paliperidone palmitate) - suspension (extended-release) - 25mg - paliperidone (paliperidone palmitate) 25mg - atypical antipsychotics

Kanada - engelska - Health Canada

janssen inc - paliperidone (paliperidone palmitate) - suspension (extended-release) - 50mg - paliperidone (paliperidone palmitate) 50mg - atypical antipsychotics

Kanada - engelska - Health Canada

janssen inc - paliperidone (paliperidone palmitate) - suspension (extended-release) - 75mg - paliperidone (paliperidone palmitate) 75mg - atypical antipsychotics

Kanada - engelska - Health Canada

janssen inc - paliperidone (paliperidone palmitate) - suspension (extended-release) - 100mg - paliperidone (paliperidone palmitate) 100mg - atypical antipsychotics

Kanada - engelska - Health Canada

janssen inc - paliperidone (paliperidone palmitate) - suspension (extended-release) - 150mg - paliperidone (paliperidone palmitate) 150mg - atypical antipsychotics

USA - engelska - NLM (National Library of Medicine)

rebel distributors corp - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 6 mg - invega® (paliperidone) extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14)] . monotherapy invega® (paliperidone) extended-release tablets are indicated for the acute treatment of schizoaffective disorder as monotherapy. adjunctive therapy invega® (paliperidone) extended-release tablets are indicated for the acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. invega® (paliperidone) is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in invega® . pregnancy category c . there are no adequate and well controlled studies of invega® in pregnant women. invega® should be used during pregnancy only if the potential benefit jus

USA - engelska - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 3 mg - invega ® (paliperidone) extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of invega ® in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. invega ® (paliperidone) extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of invega ® in schizoaffective disorder was established in two 6-week trials in adults. invega ® is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the invega ® formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. pali